Mabvax Therapeutics (MBVX) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'TELK	'
Entity Registrant Name	'TELIK INC	'
Entity Central Index Key	'0001109196	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	4,583,096

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,267	$2,229
Prepaids and other current assets	317	381
Total current assets	1,584	2,610
Total assets	1,584	2,610
Current liabilities:	'	'
Accounts payable	54	20
Accrued compensation	191	175
Accrued liabilities	160	169
Accrued contingent lease termination fee	591	591
Total current liabilities	996	955
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Common stock	46	46
Additional paid-in capital	555,140	555,139
Accumulated deficit	-554,598	-553,530
Total stockholders' equity	588	1,655
Total liabilities and stockholders' equity	$1,584	$2,610

Condensed_Statements_of_Compre

Condensed Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating costs and expenses:	'	'
Research and development	$309	$786
General and administrative	759	1,160
Total operating costs and expenses	1,068	1,946
Loss from operations	-1,068	-1,946
Interest and other income, net	'	9
Net loss	-1,068	-1,937
Basic and diluted net loss per share	($0.23)	($0.46)
Shares used to calculate basic and diluted net loss per share	4,583	4,199
Net loss	-1,068	-1,937
Other comprehensive income, net of tax:	'	'
Changes in net unrealized gains on investments	'	'
Comprehensive loss	($1,068)	($1,937)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($1,068)	($1,937)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation expense	1	140
Changes in assets and liabilities:	'	'
Other receivables	'	-1
Prepaid expenses and other current assets	64	146
Other assets	'	-104
Accounts payable	34	-121
Accrued liabilities	7	-201
Accrued facility exit costs and contingent lease termination fee	'	-622
Net cash used in operating activities	-962	-2,700
Cash flows from investing activities:	'	'
Purchases of investments	'	-1,401
Net cash used in investing activities	'	-1,401
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	'	3,570
Net cash provided by financing activities	'	3,570
Net decrease in cash and cash equivalents	-962	-531
Cash and cash equivalents at beginning of period	2,229	4,747
Cash and cash equivalents at end of period	1,267	4,216
Non-cash transaction disclosure:	'	'
Transfer of restricted investment in satisfaction of Porter Drive facility lease termination fee	'	$250

Nature_of_Operations_and_Going

Nature of Operations and Going Concern	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Nature of Operations and Going Concern	'
	1. Nature of Operations and Going Concern
	Business Overview
	Telik, Inc. (“Telik,” “we” or, the “Company”) was incorporated in the state of Delaware in October 1988. We are engaged in the discovery and development of small molecule therapeutics. We operate in only one business segment.
	We have incurred net losses since inception and we expect to incur substantial losses for the foreseeable future as we continue our research and development activities. To date, we have funded operations primarily through the sale of equity securities, non-equity payments from collaborators and interest income. The process of developing our products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive product revenue unless we, or our collaborative partners, complete clinical trials, obtain regulatory approval and successfully commercialize one or more of our products.
	Private Financing and Merger Agreement
	As our existing cash resources will only be sufficient to fund our projected operating requirements through the end of May 2014, we continue to explore various strategic alternatives, including a sale of the Company or our assets or a corporate merger. On May 12, 2014, we entered into a securities purchase agreement to sell 1,250,000 shares of our Series B Convertible Preferred Stock at $2.00 per share for a total of $2.5 million along with warrants to purchase 625,000 shares of common stock at $3.33 per share to a group of private investors led by Hudson Bay Capital Management LP, or Hudson Bay (such transaction, the “PIPE financing”). Concurrently, we entered into a merger agreement with MabVax Therapeutics, Inc., or MabVax, a privately held cancer immunotherapy company (such transaction, the “Merger”). Upon consummation of the proposed Merger, on a pro forma basis, current Telik stockholders will own 15% of the combined company and MabVax shareholders will own 85%. The $2.5 million in funding from the sale of our Series B Convertible Preferred Stock in the PIPE financing is expected to bridge us to the closing of the Merger, currently anticipated to be by early July, 2014. The Merger is subject to various closing conditions, including stockholder approval. Should we fail to consummate the Merger, we will likely proceed with the wind-down of our operations.
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	2. Basis of Presentation and Summary of Significant Accounting Policies
	We have prepared the accompanying condensed financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934, or the Exchange Act. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. We believe all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included herein. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014 or any other future period. The condensed balance sheet at December 31, 2013 has been derived from the audited financial statements at that date. You should read these condensed financial statements and notes in conjunction with our audited financial statements for the year ended December 31, 2013, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2014.
	Use of Estimates
	In preparing our financial statements to conform with GAAP, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results may differ from these estimates.

Employee_StockBased_Compensati

Employee Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Employee Stock-Based Compensation	'
	3. Employee Stock-Based Compensation
	Stock-based Compensation
	Total estimated stock-based compensation expense, related to all of our share-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		Three Months Ended
		March 31,
		2014		2013
		(in thousands)
	Research and development	$	—	$	58
	General and administrative		1		82
	Stock-based compensation expense before taxes		1		140
	Effect on net loss	$	1	$	140
	Because we had a net operating loss carryforward as of March 31, 2014, no tax benefits for the tax deductions related to stock-based compensation expense were recognized in our Condensed Statements of Comprehensive Loss. Additionally, no stock options were exercised in the three months ended March 31, 2014 and 2013. As of March 31, 2014, $5,500 of total unrecognized compensation costs, net of forfeitures, related to non-vested service based awards is expected to be recognized over a weighted average period of 1.56 years.
	Valuation Assumptions
	We used the Black-Scholes-Merton option valuation model, or the Black-Scholes model, to determine the stock-based expense recognized under ASC 718. Our expected stock-price volatility assumption was based solely on the weighted average of the historical volatility as there was insufficient traded option activity for us to use implied volatility. The expected term of stock awards under our Employee Stock Purchase Plan, or ESPP, was based on the weighted average purchase periods of each offering. The expected term of stock options granted was based on the simplified method in accordance with Staff Accounting Bulletin No. 110, or SAB 110, as our historical share option exercise experience did not provide a reasonable basis for estimation. The risk-free interest rate was based on the U.S. Treasury yield for a period consistent with the expected term of the stock award in effect at the time of the grant. There were no stock options granted and no new ESPP participants enrolled during the three months ended March 31, 2014 and 2013.

Basic_and_Diluted_Net_Loss_per

Basic and Diluted Net Loss per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Net Loss per Share	'
	4. Basic and Diluted Net Loss per Share
	Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.
	Weighted average outstanding options to purchase 250,244 and 294,835 shares of our common stock before application of the treasury stock method for the three months ended March 31, 2014 and 2013 were excluded from the diluted net loss per common share calculations because inclusion of such options would be anti-dilutive.

Fair_Value_Measurements_on_a_R

Fair Value Measurements on a Recurring Basis	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements on a Recurring Basis	'
	5. Fair Value Measurements on a Recurring Basis
	We measure certain financial assets at fair value on a recurring basis, including cash equivalents and available-for-sale securities. The fair value of these financial assets was determined based on a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. Government agency securities held in our account were recorded at their estimated fair value. These securities generally had market prices from multiple sources and it could be difficult to select the best individual price directly from the quoted prices in the active markets. Therefore we used Level 2 inputs for the valuation of these securities. Using the Level 2 inputs, a “consensus price” or a weighted average price for each of these securities was derived from a distribution-curve-based algorithm which included market prices obtained from a variety of industrial standard data providers (e.g. Bloomberg), security master files from large financial institutions and other third-party sources.
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of March 31, 2014 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
				Fair Value Measurement at March 31, 2014 Using
		March 31,		Quoted Prices in		Significant Other		Significant
		2014		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	857	$	857	$	—	$	—
	Total	$	857	$	857	$	—	$	—
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2013, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
				Fair Value Measurement at December 31, 2013 Using
		December 31,		Quoted Prices in		Significant Other		Significant
		2013		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities (presented as cash equivalents):
	Money market funds	$	458	$	458	$	—	$	—
	US government agencies		1,400		—		1,400		—
	Total	$	1,858	$	458	$	1,400	$	—
	There were no transfers between Level 1 and Level 2 measurements in the three ended March 31, 2014 and in the year ended December 31, 2013.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2014
Cash And Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	6. Cash and Cash Equivalents
	The following is a summary of estimated fair value of cash and cash equivalents:
		March 31,		December 31,
		2014		2013
		(in thousands)
	Cash and money market funds	$	1,267	$	829
	US government agencies		—		1,400
	Total	$	1,267	$	2,229
	Reported as:
	Cash and cash equivalents	$	1,267	$	2,229
	Total	$	1,267	$	2,229
	There were no realized gains or losses on sales of available-for-sale securities for the three months ended March 31, 2014 and the year ended December 31, 2013. There were no unrealized gains or losses on available-for-sale securities as of March 31, 2014 or December 31, 2013.
	As of December 31, 2013, all marketable debt securities held as available-for-sale were expected to mature in less than a year.

Accrued_Contingent_Lease_Termi

Accrued Contingent Lease Termination Fee	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Accrued Contingent Lease Termination Fee	'
	7. Accrued Contingent Lease Termination Fee
	In November 2010, we ceased the use of our facility at 3165 Porter Drive in Palo Alto, California and subleased the facility to a tenant for the remaining contractual term of our master lease, which is through May 2014. As a result, we recorded a charge of $4.7 million which included the estimated fair value of future lease-related payments less estimated net income from sublease rental offset by a reduction of $335,000 in the balance of deferred rent related to the facility as of November 30, 2010.
	On February 19, 2013, we entered into an agreement with our landlord, ARE San Francisco No. 24, LLC, or ARE, pursuant to which the premises was voluntarily surrendered, the master lease and sublease were terminated as of February 28, 2013, we were relieved of further obligations under the master lease and further rights to rental income under the sublease, and we agreed to pay a termination fee to ARE of approximately $0.7 million. Prior to the termination of these agreements, the remaining lease payments to ARE through the end of the master lease totaled approximately $4.5 million and the remaining sublease income to Telik through the same period totaled approximately $3.2 million. In addition to the termination fee, if we receive $15 million or more in additional financing in the aggregate, an additional termination fee of $591,000 will be due to ARE, but otherwise be forgiven. As a result of the termination agreement, we reversed the remaining facility exit cost liability, recorded $591,000 as accrued contingent lease termination fee and included the net charge in general and administrative expenses in the Condensed Statements of Comprehensive Loss in the quarter ended March 31, 2013.

Commitments_Contingencies

Commitments & Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments & Contingencies	'
	8. Commitments & Contingencies
	Operating Leases
	On February 27, 2013, we entered into a 21-month lease agreement for 3,075 square feet of office space at 2100 Geng Road in Palo Alto, California and relocated our corporate offices to this facility in March 2013. Upon execution of the agreement, we paid the sublessor the first month’s rent and we paid the second month’s rent on March 28, 2013, and deposited into an escrow account approximately $219,000 which represents the total rent due for the remaining term (May 1, 2013 thru November 30, 2014).
	We have no future rental payments under our non-cancelable operating leases as of March 31, 2014 and none for the year 2015 and beyond. We recorded a $591,000 contingent lease termination fee, in connection with the termination of our master lease and sublease of our Porter Drive facility, which is payable to ARE if we receive $15 million or more in additional financing in the aggregate.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	On May 12, 2014, we entered into a securities purchase agreement to sell 1,250,000 shares of our Series B Convertible Preferred Stock at $2.00 per share for a total of $2.5 million, along with warrants to purchase 625,000 shares of common stock at $3.33 per share, to a group of private investors led by Hudson Bay. Concurrently, we entered into a Merger agreement with MabVax, a privately held cancer immunotherapy company. Upon consummation of the proposed Merger, on a pro forma basis, current Telik stockholders will own 15% of the combined company and MabVax shareholders will own 85%. The $2.5 million in funding from the sale of our Series B Convertible Preferred Stock is expected to bridge us to the closing of the Merger, currently anticipated to be by early July, 2014. The Merger and PIPE financing are subject to various closing conditions, including stockholder approval.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	In preparing our financial statements to conform with GAAP, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results may differ from these estimates.

Employee_StockBased_Compensati1

Employee Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Estimated Stock-Based Compensation Expense	'
	Total estimated stock-based compensation expense, related to all of our share-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		Three Months Ended
		March 31,
		2014		2013
		(in thousands)
	Research and development	$	—	$	58
	General and administrative		1		82
	Stock-based compensation expense before taxes		1		140
	Effect on net loss	$	1	$	140

Fair_Value_Measurements_on_a_R1

Fair Value Measurements on a Recurring Basis (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	'
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of March 31, 2014 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
				Fair Value Measurement at March 31, 2014 Using
		March 31,		Quoted Prices in		Significant Other		Significant
		2014		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	857	$	857	$	—	$	—
	Total	$	857	$	857	$	—	$	—
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2013, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
				Fair Value Measurement at December 31, 2013 Using
		December 31,		Quoted Prices in		Significant Other		Significant
		2013		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities (presented as cash equivalents):
	Money market funds	$	458	$	458	$	—	$	—
	US government agencies		1,400		—		1,400		—
	Total	$	1,858	$	458	$	1,400	$	—

Cash_and_Cash_Equivalents_Tabl

Cash and Cash Equivalents (Tables)	3 Months Ended
	Mar. 31, 2014
Cash And Cash Equivalents [Abstract]	'
Summary of Estimated Fair Value of Cash and Cash Equivalents	'
	The following is a summary of estimated fair value of cash and cash equivalents:
		March 31,		December 31,
		2014		2013
		(in thousands)
	Cash and money market funds	$	1,267	$	829
	US government agencies		—		1,400
	Total	$	1,267	$	2,229
	Reported as:
	Cash and cash equivalents	$	1,267	$	2,229
	Total	$	1,267	$	2,229

Nature_of_Operations_and_Going1

Nature of Operations and Going Concern - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	12-May-14	12-May-14
	Segment	Subsequent Event [Member]	Subsequent Event [Member]
		Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]
			MabVax [Member]
Organization And Nature Of Operations [Line Items]	'	'	'
Number of business segments	1	'	'
Series B Convertible preferred stock issued	'	1,250,000	'
Series B Convertible preferred stock issued price per share	'	$2	'
Purchase of Series B convertible preferred stock	'	$2.50	'
Warrants to purchase shares of common stock	'	625,000	'
Warrants to purchase shares of common stock price per share	'	3.33	'
Percentage of ownership	'	15.00%	85.00%

Employee_StockBased_Compensati2

Employee Stock-Based Compensation - Schedule of Estimated Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense before taxes	$1	$140
Effect on net loss	1	140
Research and development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense before taxes	'	58
General and administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense before taxes	$1	$82

Employee_StockBased_Compensati3

Employee Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Tax deductions related to stock-based compensation	$0	'
Stock options exercised	0	0
Unrecognized compensation costs, net of forfeitures	$5,500	'
Expected to be recognized over weighted average period	'1 year 6 months 22 days	'

Employee_StockBased_Compensati4

Employee Stock-Based Compensation - New ESPP Offerings and Stock Option Granted - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
New enrolled ESPP participants	0	0
Stock options granted	0	0

Basic_and_Diluted_Net_Loss_per1

Basic and Diluted Net Loss per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Shares of common stock excluded from diluted net loss per common share calculations	250,244	294,835

Fair_Value_Measurements_on_a_R2

Fair Value Measurements on a Recurring Basis - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	$857	$1,858
US government agencies [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	1,400
Money market funds [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	857	458
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	857	458
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | US government agencies [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	'
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money market funds [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	857	458
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	1,400
Significant Other Observable Inputs (Level 2) [Member] | US government agencies [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	1,400
Significant Other Observable Inputs (Level 2) [Member] | Money market funds [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member] | US government agencies [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member] | Money market funds [Member]	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'
Financial assets	'	'

Fair_Value_Measurements_on_a_R3

Fair Value Measurements on a Recurring Basis - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Transfer of securities between Level 1 and Level 2 measurements	$0	$0

Cash_and_Cash_Equivalents_Summ

Cash and Cash Equivalents - Summary of Estimated Fair Value of Cash, Cash Equivalents and Investments (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	$1,267	$2,229	'	'
Cash and cash equivalents	1,267	2,229	4,216	4,747
Total	1,267	2,229	'	'
Cash and money market funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	1,267	829	'	'
US government agencies [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	'	$1,400	'	'

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Cash And Cash Equivalents [Abstract]	'	'
Realized gains or losses on sales of available-for-sale investments	$0	$0
Unrealized gains or losses on available-for-sale securities	$0	$0

Accrued_Contingent_Lease_Termi1

Accrued Contingent Lease Termination Fee - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		1 Months Ended
	Feb. 28, 2013	Mar. 31, 2014	Dec. 31, 2013	Nov. 30, 2010
				Facility Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Estimated fair value of future lease-related payments	'	'	'	$4,700,000
Deferred rent	'	'	'	335,000
Lease and sublease expiration date	'	'	'	31-May-14
Termination of master as well as sublease	'	28-Feb-13	'	'
Termination fees payable	'	700,000	'	'
Remaining master lease payments	4,500,000	'	'	'
Additional termination fee due	'	591,000	'	'
Contingent lease termination fee	'	591,000	591,000	'
Additional financing amount	'	15,000,000	'	'
Remaining sublease income	$3,200,000	'	'	'

Commitments_Contingencies_Addi

Commitments & Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Feb. 26, 2013	Mar. 31, 2014	Mar. 31, 2014
			2100 Geng Road in Palo Alto, California [Member]	2100 Geng Road in Palo Alto, California [Member]	Porter Drive [Member]
			sqft
Operating Leased Assets [Line Items]	'	'	'	'	'
Term of lease agreement	'	'	'21 months	'	'
Amount deposited in escrow for rent due for remaining lease period	'	'	$219,000	'	'
Remaining term of rent deposited in escrow	'	'	'	'May 1, 2013 thru November 30, 2014	'
Number of square feet	'	'	3,075	'	'
Future rental payments under our non-cancelable operating leases	'	'	'	0	'
Future rental payments under our non-cancelable operating leases for the year 2015 and thereafter	'	'	'	0	'
Contingent lease termination fee	591,000	591,000	'	'	591,000
Additional financing or licensing payments	$15,000,000	'	'	'	$15,000,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], Series B Convertible Preferred Stock [Member], USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	12-May-14
Subsequent Event [Line Items]	'
Series B Convertible preferred stock issued	1,250,000
Series B Convertible preferred stock issued price per share	$2
Purchase of Series B convertible preferred stock	$2.50
Warrants to purchase shares of common stock	625,000
Warrants to purchase shares of common stock price per share	3.33
Percentage of ownership	15.00%
MabVax [Member]	'
Subsequent Event [Line Items]	'
Percentage of ownership	85.00%